Description: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer�s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.Over 70 therapeutic antibody programs based on the company�s technologies are currently in development, of which 20 are in clinical trials. The company�s most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR208 and MOR202, both for the treatment of cancer.MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Home Page: www.morphosys.com
Semmelweisstrasse 7
Planegg,
82152
Germany
Phone:
49 89 89927 0
Officers
| Name | Title |
|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman of Management Board, MD & CEO |
| Mr. Sung H. Lee | CFO & Member of Management Board |
| Dr. Marlies Sproll | Special Adviser to the Chief Exec. Officer |
| Mr. Klaus De Wall | Head of Accounting & Tax |
| Ms. Lara Smith Weber | Head of Controlling, Corp. Fin. & Corp. Devel. |
| Dr. Margit Urban | Head of Discovery Alliances & Technologies |
| Dr. Anja Pomrehn | Sr. VP & Head of Investor Relations |
| Ms. Charlotte Lohmann | Sr. VP of Legal, Compliance & IP and Gen. Counsel |
| Mr. Thomas Biegi | VP & Head of Corp. Communications |
| Ms. Maria Castresana | Sr. VP & Global Head of HR |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 322.5806 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.2501 |
| Price-to-Sales TTM: | 2.2607 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 627 |